Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

Patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) harboring BIM deletion polymorphism (BIM deletion) have poor responses to EGFR TKI. Mechanistically, the BIM deletion induces preferential splicing of the non‐functional exon 3‐containing isoform over th...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Shinji, Hase, Tetsunari, Shimizu, Shinobu, Ando, Masahiko, Hata, Akito, Murakami, Haruyasu, Kawakami, Takahiro, Nagase, Katsuhiko, Yoshimura, Kenichi, Fujiwara, Tadami, Tanimoto, Azusa, Nishiyama, Akihiro, Arai, Sachiko, Fukuda, Koji, Katakami, Nobuyuki, Takahashi, Toshiaki, Hasegawa, Yoshinori, Ko, Tun Kiat, Ong, S. Tiong, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004511/
https://www.ncbi.nlm.nih.gov/pubmed/31782583
http://dx.doi.org/10.1111/cas.14260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004511/
https://www.ncbi.nlm.nih.gov/pubmed/31782583
http://dx.doi.org/10.1111/cas.14260

Ejemplares similares